With a strategic emphasis on oncology, we have built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. Currently, three of them are being investigated in clinical trials, which are Buparlisib (AN2025), Pelareorep (AN1004) and an oral EP4 antagonist (AN0025).